By 2023, global follicle stimulating hormone (FSH) consumption will get to 46081 K Doses

By 2023, global follicle stimulating hormone (FSH) consumption will get to 46081 K Doses QYRESEARCH FOCUS ON MARKET SURVEY AND RESEARCH

www.qyresearch.com

CONTACT

Beijing Hengzhou Bozhi International Information Consulting Web: qyresearchglobal.com | qyresearch.com TEL:+86-13660489419, Office:+86-2022093278 Media: press@qyresearch.com

Marketing: sales@qyresearchglobal.com Facebook: @QYResearchOfficial Twitter: @QYResearch_ Wechat Official Account: QYResearch, Weibo: 恒州博智

QYResearch • Follicle stimulating hormone (FSH) is a hormone made by the pituitary gland that affects the gonads (female ovaries and males testes). It is mainly used to treat infertility disease and assisted reproductive technology. At present, this product cannot be replaced in the treatment of infertility. • There are two methods to produce follicle stimulating hormone, recombinant DNA technology and urine extraction technology. Due to less pollution, recombinant FSH takes large proportion in market. In 2016, recombinant FSH takes about 82.14%. While, recombinant DNA technology is difficult and there are only few company own this technology.

QYR

• Currently, There are only several companies producing this product, such as Merck Serono, MSD, IBSA, Ferring, Livzon and Techwell etc. Merck Serono and MSD are top two companies in the world. In 2016, Merck Serono takes about 58.70% of global follicle stimulating hormone revenue. MSD takes about 26.29% of global follicle stimulating hormone revenue.

QYR

• Global follicle stimulating hormone (FSH) mainly consumed in Asia Pacific, Europe and North America. In 2016, Asia Pacific follicle stimulating hormone (FSH) revenue takes about 23.00% in global. Europe takes 34.84% of global follicle stimulating hormone (FSH) revenue. North America takes 27.21%. The product has high degree of monopoly. • In the past five years, global follicle stimulating hormone (FSH) sales varied from 35713 K Doses in 2012 to 39777 K Doses in 2016, with an average increase rate of 2.73%. Meanwhile, global FSH revenue also varied from 1417.63 Million USD in 2012 to 1350.26 Million USD in 2016.

QYR In the future, with increase of pressure from work, global Infertility patients may increase. So, global follicle stimulating hormone (FSH) demand will continue to improve. By 2023, global follicle stimulating hormone (FSH) consumption will get to 46081 K Doses.

Click to view the full report: https://www.qyresearch.com/index/detail/152704/globalfollicle-stimulating-hormone-market